Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Sex differences and sex steroids influence on the presentation and severity of cardiovascular autonomic neuropathy of patients with type 1 diabetes

  • Nattero Chávez, María Lia
  • Insenser Nieto, María Rosa
  • Quintero Tobar, Alejandra
  • Fernández Durán, Elena
  • Dorado Avendaño, Beatriz
  • Fiers, Tom
  • Kaufman, Jean Marc
  • Luque Ramírez, Manuel
  • Escobar Morreale, Héctor Francisco|||0000-0002-6890-1644
Background: Sex differences characterize cardiovascular outcomes in patients with type 1 diabetes. Cardioauto‑ nomic neuropathy is a common complication of type 1 diabetes that associates increased morbi-mortality. Data regarding the interplay between sex and cardiovascular autonomic neuropathy are scarce and controversial in these patients. We aimed to address sex-related differences in the prevalence of seemingly asymptomatic cardioautonomic neuropathy in type 1 diabetes, and their associations with sex steroids. Methods We conducted a cross-sectional study including 322 consecutively recruited patients with type 1 diabetes. Cardioautonomic neuropathy was diagnosed using Ewing’s score and power spectral heart rate data. We assessed sex hormones by liquid chromatography/tandem mass spectrometry. Results When considering all subjects as a whole, asymptomatic cardioautonomic neuropathy prevalence was not significantly different between women and men. When age was taken into account, the prevalence of cardioauto‑ nomic neuropathy was similar among young men and those>50 years. However, in women>50 years, the preva‑ lence of cardioautonomic neuropathy doubled that of young women [45.8% (32.6; 59.7) vs. 20.4% (13.7; 29.2), respec‑ tively]. The OR of having cardioautonomic neuropathy was 3.3 higher in women>50 years than in their younger counterparts. Furthermore, women presented more severe cardioautonomic neuropathy than men. These differences were even more marked when women were classified according their menopausal status instead of age. Peri- and menopausal women had an OR 3.5 (1.7; 7.2) of having CAN compared with their reproductive-aged counterparts [CAN prevalence: 51% (37; 65) vs. 23% (16; 32), respectively]. A binary logistic regression model (R2 : 0.161; P=0.001) displayed age>50 years as a significant determinant of cardioautonomic neuropathy only in women. Androgens were positively associated with heart rate variability in men, and negatively in women. Accordingly, cardioautonomic neuropathy was associated with increased testosterone/estradiol ratio in women but to decreased testosterone con‑ centrations in men., Society of Endocrinology, Nutrition and Diabetes of the Community of Madrid (SENDIMAD), Instituto de Salud Carlos III
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Investigating the link between intermediate metabolism, sexual dimorphism, and cardiac autonomic dysfunction in patients with Type 1 Diabetes

  • Insenser Nieto, María Rosa
  • Nattero Chávez, María Lia
  • Luque Ramírez, Manuel
  • Lope Quiñones, Sara De
  • Quintero Tobar, Alejandra
  • Samino Gené, Sara
  • Amigó Grau, Núria
  • Dorado Avendaño, Beatriz
  • Fiers, Tom
  • Escobar Morreale, Héctor Francisco|||0000-0002-6890-1644
13 p., Sexual dimorphism influences cardiovascular outcomes in type 1 diabetes (T1D), with women facing a higher relative risk of macrovascular events compared to men, especially after menopause. This study hypothesizes that abnormalities in intermediate metabolism may be associated with cardiac autonomic neuropathy (CAN) in T1D. We aim to assess low molecular weight metabolites (LMWM) as markers of CAN in T1D, considering the effects of sexual dimorphism and age. In this cross-sectional study, we included 323 subjects with T1D (147 women and 176 men), with a mean age of 41 ± 13 years. A total of 44 women and 41 men were over 50 years old. CAN was assessed using Ewing's tests, and serum metabolites were analyzed by proton nuclear magnetic resonance spectroscopy (1H-NMR). Patients with CAN had lower levels of valine, isoleucine, and threonine, and higher levels of lactate, compared to those without CAN. These differences persisted after adjusting for BMI and estimated glucose disposal rate (eGDR). In a logistic regression model (R² = 0.178, p < 0.001), the main determinants of CAN included isoleucine [Exp(?) = 0.972 (95% CI 0.952; 0.003)], age [Exp(?) = 1.031 (95% CI 1.010; 1.053)], A1c [Exp(?) = 1.361 (95% CI 1.058; 1.752)], and microangiopathy [Exp(?) = 2.560 (95% CI 1.372; 4.778)]. Sex influenced LMWM profiles, with over half of the metabolites differing between men and women. However, no interactions were found between CAN and sex, or between sex, age, and CAN, on metabolomics profiles. Our findings suggest an association between CAN and LMWM levels in T1D. The sexual dimorphism observed in amino acid metabolites was unaffected by the presence of CAN., Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Fondo Europeo de Desarrollo Regional (FEDER), Centro de Investigación Biomédica en Red. Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Switching to an advanced hybrid closed-loop system in real-world practice improves hypoglycemia awareness and metabolic control in adults with type 1 diabetes, particularly in those with impaired perception of hypoglycemia symptoms

  • Nattero Chávez, María Lia
  • Lecumberri Pascual, Edurne
  • Calle Villa, Esther de la
  • Bayona Cebada, Ane
  • Ruiz Gracia, Teresa
  • Quintero Tobar, Alejandra
  • Lorenzo, Mar
  • Sánchez, Cristina
  • Izquierdo, Ana
  • Luque Ramírez, Manuel
  • Escobar Morreale, Héctor Francisco|||0000-0002-6890-1644
8 p., Aims: To evaluate the efficacy of an advance closed-loop (AHCL) system in restoring awareness of hypoglycemia in patients with type 1 diabetes (T1D). Methods: We conducted a prospective study including 46 subjects with T1D flash glucose monitoring (FGM) or continuous glucose monitoring (CGM) switching to a Minimed 780G® system. Patients were classified in three groups according to the therapy used before switching to Minimed® 780G: multiple dose insulin (MDI) therapy + FGM (n = 6), continuous subcutaneous insulin infusion + FGM (n = 21), and sensor-augmented pump with predictive low-glucose suspend (n = 19). FGM/CGM data were analyzed at baseline, after 2 and 6 months on AHCL. Clarke's score of hypoglycemia awareness was compared at baseline and 6 months recordings. We also compared the efficacy of the AHCL system in improving A1c among patients with appropriate perception of symptoms of hypoglycemia compared to those presenting with impaired awareness of hypoglycemia (IAH). Results: Participants had a mean age of 37 ± 15 and a diabetes duration of 20 ± 10 years. At baseline, 12 patients (27%) showed IAH as defined by a Clarke's score ? 3. Patients with IAH were older and had lower estimated glomerular filtration rate (eGFR) compared with those who did not have IAH; with no differences in baseline CGM metrics or A1c. An overall decrease in A1c was observed after 6 months on AHCL system (from 6.9 ± 0.5% to 6.7 ± 0.6%, P < 0.001), regardless of prior insulin therapy. The improvement in metabolic control was greater in patients with IAH, showing a reduction in A1c from 6.9 ± 0.5 to 6.4 ± 0.4% vs 6.9 ± 0.5 to 6.8 ± 0.6% (P = 0.003), showing a parallel increase in total daily boluses of insulin and automatic bolus correction administered by the AHCL system. In patients with IAH Clarke's score decreased from 3.6 ± 0.8 at baseline to 1.9 ± 1.6 after 6 months (P < 0.001). After 6 months on AHCL system, only 3 patients (7%) presented with a Clarke's score ? 3, resulting in an absolute risk reduction of 20% (95% confidence interval: 7-32) of having IAH. Conclusions: Switching from any type of insulin administration to AHCL system improves restoration of hypoglycemia awareness and metabolic control in patients with T1D, particularly in adults with impaired perception of hypoglycemia symptoms., Instituto de Salud Carlos III, Centro de Investigación Biomédica en REd. Diabetes y Enfermerdades Metabólicas Asociadas (CIBERDEM), Ministerio de Economía y Competitividad, Fondo Europeo de Desarrollo Regional (FEDER) "Una manera de hacer Europa", Sociedad de Endocrinología, Nutrición y Diabetes de la Comunidad de Madrid (SENDIMAD)